Search Results

There are 2998616 results for: content related to: Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients

  1. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone

    Drug Development Research

    Volume 49, Issue 4, April 2000, Pages: 238–244, Jouko Savolainen, Markus Forsberg, Hannu Taipale, Pekka T. Männistö, Kristiina Järvinen, Jukka Gynther, Pekka Jarho and Tomi Järvinen

    Article first published online : 12 JUN 2000, DOI: 10.1002/1098-2299(200004)49:4<238::AID-DDR2>3.0.CO;2-V

  2. You have free access to this content
    Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities

    Pharmacology & Toxicology

    Volume 90, Issue 6, June 2002, Pages: 327–332, Markus Forsberg, Jouko Savolainen, Tomi Järvinen, Jukka Leppänen, Jukka Gynther and Pekka T. Männistö

    Article first published online : 1 JUL 2002, DOI: 10.1034/j.1600-0773.2002.900606.x

  3. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Article first published online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  4. Twelve-month safety of entacapone in patients with Parkinson’s disease

    European Journal of Neurology

    Volume 8, Issue 1, January 2001, Pages: 53–60, V. V. Myllylä, E.-R. Kultalahti, H. Haapaniemi, M. Leinonen and FILOMEN Study Group

    Article first published online : 21 DEC 2001, DOI: 10.1046/j.1468-1331.2001.00168.x

  5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

    Intervention Review

    The Cochrane Library

    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley and Alex Furmston

    Published Online : 7 JUL 2010, DOI: 10.1002/14651858.CD007166.pub2

  6. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Article first published online : 21 OCT 2011, DOI: 10.1002/mds.23829

  7. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug

    European Journal of Neurology

    Volume 11, Issue 9, September 2004, Pages: 593–606, L. Brusa, A. Bassi, G. Lunardi, E. Fedele, A. Peppe, A. Stefani, P. Pasqualetti, P. Stanzione and M. Pierantozzi

    Article first published online : 15 SEP 2004, DOI: 10.1111/j.1468-1331.2004.00860.x

  8. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)

    Acta Neurologica Scandinavica

    Volume 105, Issue 4, April 2002, Pages: 245–255, W. H. Poewe, G. Deuschl, A. Gordin, E.-R. Kultalahti, M. Leinonen and the Celomen Study Group

    Article first published online : 3 APR 2002, DOI: 10.1034/j.1600-0404.2002.1o174.x

  9. Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Article first published online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  10. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

    European Journal of Neurology

    Volume 10, Issue 2, March 2003, Pages: 137–146, J. P. Larsen, J. Worm-Petersen, Å. Sidén, A. Gordin, K. Reinikainen, M. Leinonen and the NOMESAFE Study Group

    Article first published online : 26 FEB 2003, DOI: 10.1046/j.1468-1331.2003.00559.x

  11. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004554.pub2

  12. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets

    Movement Disorders

    Volume 12, Issue 6, November 1997, Pages: 935–945, Lance A. Smith, Ariel Gordin, Dr. Peter Jenner and C. David Marsden

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870120616

  13. You have free access to this content
    Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose

    British Journal of Clinical Pharmacology

    Volume 54, Issue 4, October 2002, Pages: 363–371, Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola and Kari Reinikainen

    Article first published online : 23 OCT 2002, DOI: 10.1046/j.1365-2125.2002.01654.x

  14. Pooled analysis of phase III with entacapone in Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 130, Issue 4, October 2014, Pages: 239–247, M. Kuoppamäki, M. Vahteristo, J. Ellmén and K. Kieburtz

    Article first published online : 3 SEP 2014, DOI: 10.1111/ane.12278

  15. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial

    Annals of Neurology

    Volume 69, Issue 1, January 2011, Pages: 111–118, Jean-Christophe Corvol, Cécilia Bonnet, Fanny Charbonnier-Beaupel, Anne-Marie Bonnet, Marie-Hélène Fiévet, Agnès Bellanger, Emmanuel Roze, Gayané Meliksetyan, Mouna Ben Djebara, Andreas Hartmann, Lucette Lacomblez, Cédric Vrignaud, Noël Zahr, Yves Agid, Jean Costentin, Jean-Sébastien Hulot and Marie Vidailhet

    Article first published online : 28 JAN 2011, DOI: 10.1002/ana.22155

  16. You have free access to this content
    Entacapone promotes cAMP-dependent colonic Cl secretion in rats

    Neurogastroenterology & Motility

    Volume 23, Issue 7, July 2011, Pages: 657–e277, L.-S. Li, L.-F. Zheng, J.-D. Xu, T. Ji, H. Guo, X.-F. Li, Y. Li, Y. Zhang and J.-X. Zhu

    Article first published online : 19 APR 2011, DOI: 10.1111/j.1365-2982.2011.01715.x

  17. You have free access to this content
    Endothelial dysfunction in gestational hypertension induced by catechol-O-methyltransferase inhibition

    Experimental Physiology

    Volume 98, Issue 3, March 2013, Pages: 856–866, M. Hernandez, I. Hernandez, F. Rodriguez, M. Pertegal, B. Bonacasa, M. G. Salom, T. Quesada and F. J. Fenoy

    Article first published online : 23 JAN 2013, DOI: 10.1113/expphysiol.2012.067389

  18. Bimodal administration of entacapone in Parkinson’s disease patients improves motor control

    European Journal of Neurology

    Volume 15, Issue 3, March 2008, Pages: 268–273, L. Bet, S. R. Bareggi, F. Pacei, G. Bondiolotti, G. Meola and A. H. V Schapira

    Article first published online : 14 FEB 2008, DOI: 10.1111/j.1468-1331.2007.02043.x

  19. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease

    European Journal of Neurology

    Volume 2, Issue 4, September 1995, Pages: 341–347, S. Kaakkola, H. Teräväinen, S. Ahtila, M. Karlsson, T. Naukkarinen, H. Rita and A. Gordin

    Article first published online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1995.tb00137.x

  20. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque

    European Journal of Neuroscience

    Volume 37, Issue 5, March 2013, Pages: 831–838, Philippe Huot, Tom H. Johnston, Tessa Snoeren, James B. Koprich, Michael P. Hill, Susan H. Fox and Jonathan M. Brotchie

    Article first published online : 3 JAN 2013, DOI: 10.1111/ejn.12093